[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"rheumatic-diseases\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:rheumatic-diseases":24},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,25,0,[8,44,91,120,147,174,214,242,269,289,319,354,380,405,427,451,470,499,528,548,575,600,628,656,681],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":26,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":4,"leadSponsor":40,"locationsCount":43},"100059944","studies-of-the-natural-history-of-rheumatic-diseases-100059944",false,"NCT00024479","Studies of the Natural History of Rheumatic Diseases","* INCLUSION CRITERIA:\n\nKnown or suspected rheumatic disease\n\nAge greater than or equal to 18 years\n\nWillingness and capacity to provide informed consent.\n\nEXCLUSION CRITERIA:\n\nPatients will be excluded if any of the inclusion criteria cannot be met.\n\nWomen who are pregnant or breastfeeding at the time of enrollment.","ALL","18 Years","100 Years",{"count":19,"type":20},7500,"ESTIMATED","OBSERVATIONAL","This study will explore the causes of rheumatic diseases and why many of them affect certain minority communities more severely. Rheumatic diseases may cause joint pain, stiffness or swelling. Some can involve bones, muscles, tendons or ligaments. Some cause abnormalities of the immune system-the body s defense against disease. Some rheumatic diseases are painful or deforming and some can be life threatening. Information obtained from this study will be used to learn about the disparities in rheumatic disease in the minority community and to design further, more targeted, research studies to address this issue.\n\nPatients with known or suspected rheumatic disease 18 years of age or older may be eligible for this study. Candidates will undergo a medical history and physical examination to confirm the diagnosis of rheumatic disease and determine what is needed for evaluation and treatment.\n\nParticipants will receive standard medical care for rheumatic disease and arthritis. No experimental treatments, medications or procedures will be included in this study. Procedures may include routine blood tests for blood chemistries, cell counts, and antibodies commonly found in patients with rheumatic disease; a urine test for proteins and cells; and X-rays and other imaging tests to check for abnormalities in the lungs or other organs. All medical information will be kept confidential.\n\nPatients who are found to be eligible for other current NIH research studies will be offered an opportunity to participate in these studies.",[24,25],"Rheumatic Diseases","Arthritis",[27,28,29,30,31,32],"Minorities","Rheumatic Disease","Community Based","Natural History","Ethnicity","Health Disparities","RECRUITING","2026-06-23",{"date":36,"type":37},"2026-06-24","ACTUAL",{"date":39,"type":37},"2001-10-03",{"name":41,"class":42},"National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)","NIH",1,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":50,"eligibilityCriteria":51,"healthyVolunteers":52,"sex":15,"minAge":16,"maxAge":53,"enrollmentInfo":54,"targetDuration":4,"studyType":56,"phases":57,"briefSummary":59,"conditions":60,"keywords":73,"overallStatus":80,"whyStopped":4,"lastUpdateSubmitDate":81,"lastUpdatePostDateStruct":82,"startDateStruct":84,"completionDateStruct":86,"leadSponsor":88,"locationsCount":43},"100600783","hyperthermia-in-patients-with-chronic-primary-pain---effects-on-thermoregulation-somatosensory-system-and-movement-evoked-pain-100600783","NCT07101978","Hyperthermia in Patients With Chronic Primary Pain - Effects on Thermoregulation, Somatosensory System and Movement Evoked Pain","Hyperthermia in Healthy and Patients With Chronic Primary Pain - Effects on Thermoregulation, Somatosensory System, Movement Evoked Pain (HYPPRI-1)","HYPPRI-1","Inclusion Criteria:\n\npatients:\n\n* Confirmed diagnosis of widespread pain (ICD-11 MG30.01)\n* Widespread Pain Index (WPI) ≥ 7 and Symptom Severity (SS) scale ≥ 5 or WPI) ≥ 3 and SS ≥ 9,\n* Pain \\>= 3 month and VAS \\>= 4,0\n* Body - infrared-A-Bulb Distance \\\u003C 38cm (overweight participants)\n* Signed declaration of consent\n\nhealthy:\n\n* No chronic illnesses\n* No acute infections\n* No regular medication: To avoid interactions\n* BMI ≤ 40kg\u002Fcm2\n* Mental health: No psychiatric diagnoses or psychotropic medication in your medical history\n\nExclusion Criteria:\n\n* Participation in other clinical studies\n* Contraindications for hyperthermia (severe cardiovascular diseases, tumour diseases, acute infections, pregnant and breastfeeding women)\n* Acute and \u002F or feverish microbial infections\n* Participants with severe somatic, rheumatic concomitant endocrine or neurological diseases, in particular neurological diseases associated with cognitive disorders, severe liver or kidney and cardiac diseases\n* participants who are permanently treated with opioids, cannabis, immunosuppressive drugs (e.g. corticoids, immunosuppressants) or alpha\u002Fbeta-A(nta)gonists due to a disease from the group described above\n* participants with pain due to a serious psychiatric illness (bipolar disorder, psychosis, personality disorder, severe depression, substance abuse) and serious systemic or neurological disorders\n* pregnancy or breastfeeding (for women)\n* Intake of medication within 6 weeks that inhibits the reuptake of the neurotransmitter serotonin or binds to receptors of this neurotransmitter group",true,"70 Years",{"count":55,"type":20},60,"INTERVENTIONAL",[58],"NA","This study, in a quasi-experimental matched two-group pre-post design, investigates the effect of serial water-filtered whole-body hyperthermia on circadian core body temperature, the somatosensory system (nociception) and the movement evoked pain in healthy and patients with chronic primary pain (e.g., fibromyalgia). The intervention lasts 3 weeks with two treatment sessions per week.",[61,62,63,64,24,65,66,67,68,69,70,71,72],"Hyperthermia","Chronic Primary Pain","Widespread Pain","Muscular Disease","Musculoskeletal Diseases","Neuromuscular Disease","Fibromyalgia","Circadian Rhythm","Body Temperature Changes","Somatosensory Function","Quantitative Sensory Testing","Healthy",[74,75,76,77,78,79],"hyperthermia","widespread pain","chronic primary pain","circadian body temperature","quantitative sensory testing","healthy","NOT_YET_RECRUITING","2026-05-29",{"date":83,"type":37},"2026-06-02",{"date":85,"type":20},"2026-08-01",{"date":87,"type":20},"2028-12-31",{"name":89,"class":90},"Bern University of Applied Sciences","OTHER",{"id":92,"slug":93,"hasResults":11,"nctId":94,"briefTitle":95,"officialTitle":95,"acronym":4,"eligibilityCriteria":96,"healthyVolunteers":11,"sex":15,"minAge":97,"maxAge":4,"enrollmentInfo":98,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":100,"conditions":101,"keywords":107,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":111,"lastUpdatePostDateStruct":112,"startDateStruct":114,"completionDateStruct":116,"leadSponsor":118,"locationsCount":43},"100614362","the-rheumsafer-study-improving-medication-appropriateness-in-people-with-rheumatic-conditions-100614362","NCT07278609","The RheumSafer Study: Improving Medication Appropriateness in People With Rheumatic Conditions","Inclusion Criteria:\n\n* Aged ≥60\n* Followed by a rheumatologist at MUHC for an inflammatory arthritis (such as rheumatoid arthritis, psoriatic arthritis, spondyloarthritis), a systemic autoimmune rheumatic disease (such as systemic lupus erythematosus, inflammatory myositis, systemic sclerosis, antiphospholipid antibody syndrome, Sjogren syndrome, systemic vasculitis), or another chronic musculoskeletal or rheumatic condition (such as crystal arthritis and osteoarthritis)\n* Currently taking ≥5 regular medications and ≥1 PIM\n* Anticipated ongoing clinical follow-up in rheumatology at an interval of every 3-9 months\n\nExclusion Criteria:\n\n* Unable to provide informed consent\n* Acute life-threatening illness or life expectancy \\\u003C12 months","60 Years",{"count":99,"type":20},100,"The goal of this prospective observational quality improvement study is to determine if a physician tool, MedSafer, combined with educational brochures for patients, can help to reduce the use of 'potentially inappropriate medications' (PIMs) in adults aged 60 and over with rheumatic conditions and polypharmacy (taking 5 or more regular medications).\n\nResearchers will follow participants during usual rheumatic disease care. They will compare the rate of PIM deprescribing (stopping medications or reducing the dose) before and after the introduction of the following interventions:\n\n* MedSafer reports provided to treating physicians\n* EMPOWER consumer brochures provided to participants\n\nParticipants will complete 4 study visits over 18-20 months during which researchers will collect information on medication changes, serious adverse events (emergency visits or hospitalizations), and quality of life.",[24,102,103,104,105,106],"Inflammatory Arthritis","Systemic Lupus Erthematosus (SLE)","Vasculitis","Muskuloskeletal Diseases","Systemic Autoimmune Diseases",[108,109,24,110],"Deprescribing","Potentially inappropriate medications","Polypharmacy","2026-04-27",{"date":113,"type":37},"2026-05-01",{"date":115,"type":37},"2025-10-29",{"date":117,"type":20},"2028-06-30",{"name":119,"class":90},"McGill University Health Centre\u002FResearch Institute of the McGill University Health Centre",{"id":121,"slug":122,"hasResults":11,"nctId":123,"briefTitle":124,"officialTitle":125,"acronym":4,"eligibilityCriteria":126,"healthyVolunteers":11,"sex":15,"minAge":127,"maxAge":53,"enrollmentInfo":128,"targetDuration":4,"studyType":56,"phases":130,"briefSummary":131,"conditions":132,"keywords":134,"overallStatus":80,"whyStopped":4,"lastUpdateSubmitDate":139,"lastUpdatePostDateStruct":140,"startDateStruct":142,"completionDateStruct":143,"leadSponsor":145,"locationsCount":43},"100631761","effects-of-aerobic-exercise-in-rheumatoid-arthritis-100631761","NCT07504887","Effects of Aerobic Exercise in Rheumatoid Arthritis","Evaluation of the Effects of Aerobic Exercise Therapy on Quality of Life, Functional Capacity, Mood, Fatigue, and Inflammatory Markers in Patients With Rheumatoid Arthritis","Inclusion Criteria:\n\n* Diagnosed with RA according to ACR\u002FEULAR 2010 criteria\n* Female patients aged 30-70 years\n* Low disease activity (DAS-28 \\\u003C 3.2)\n* Voluntary participation\n\nExclusion Criteria:\n\n* Cardiovascular diseases (CAD, heart failure, etc.)\n* Respiratory diseases\n* Neurological disorders\n* BMI \\> 35\n* Malignancy\n* Pregnancy or breastfeeding\n* Recent medication change (last 3 months)\n* Musculoskeletal conditions preventing exercise","30 Years",{"count":129,"type":20},64,[58],"This study aims to evaluate the effects of aerobic exercise therapy on quality of life, functional capacity, mood, and fatigue in patients with rheumatoid arthritis. Additionally, the study investigates the impact of aerobic exercise on inflammatory markers, pain, and disease activity.",[24,133],"Rheumatic Disorder",[135,136,137,138],"RHEUMATIC DISEASE","RHEUMATIC ARTRIT","PAIN","PHYSICAL MEDICINE AND REHABILITATION","2026-03-26",{"date":141,"type":37},"2026-04-01",{"date":141,"type":20},{"date":144,"type":20},"2027-01-30",{"name":146,"class":90},"Kutahya Health Sciences University",{"id":148,"slug":149,"hasResults":11,"nctId":150,"briefTitle":151,"officialTitle":152,"acronym":153,"eligibilityCriteria":154,"healthyVolunteers":11,"sex":15,"minAge":155,"maxAge":4,"enrollmentInfo":156,"targetDuration":4,"studyType":56,"phases":158,"briefSummary":160,"conditions":161,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":165,"lastUpdatePostDateStruct":166,"startDateStruct":168,"completionDateStruct":170,"leadSponsor":172,"locationsCount":43},"100630620","early-phase-1-exploratory-clinical-study-on-the-safety-and-efficacy-of-anti--cd19bcma-car-nk-cell-injection-for-the-treatment-of-refractory-pediatric-rheumatic-diseases-100630620","NCT07490041","Exploratory Clinical Study on the Safety and Efficacy of Anti- CD19\u002FBCMA CAR-NK Cell Injection for the Treatment of Refractory Pediatric Rheumatic Diseases","Exploratory Clinical Study on the Safety and Efficacy of Anti- CD19\u002FBCMA CAR-NK Cell Injection for the Treatment of Relapsed\u002FRefractory Pediatric Rheumatic Diseases","Cell therapy","Common Inclusion Criteria:\n\n1. . Gender unrestricted, age ≥5 years;\n2. . The patient or their legal guardian agrees to participate in this clinical trial and signs the informed consent form, indicating their understanding of the trial's purpose and procedures and willingness to participate;\n3. . Peripheral blood B cells confirmed by flow cytometry to express CD19, with a B cell count \\>5 cells\u002FuL;\n4. . If previously treated with B cell-targeted therapy, peripheral blood B cell count at screening has returned to normal or above the pre-treatment level;\n5. . Echocardiography indicates basically normal cardiac structure and left ventricular ejection fraction (LVEF) ≥55%; electrocardiogram shows no significant abnormalities;\n6. . Liver function: aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤3.0×ULN, total bilirubin (TBIL) ≤2.0×ULN;\n7. . Renal function: estimated glomerular filtration rate (eGFR) ≥30 mL\u002Fmin\u002F1.73m²; (If eGFR \\\u003C30 mL\u002Fmin\u002F1.73m² and\u002For undergoing renal replacement therapy, the subject may be considered for enrollment after the investigator's assessment that the benefit outweighs the risk and with full informed consent from the patient\u002Fguardian);\n8. . Pulmonary function: No severe pulmonary lesions, blood oxygen saturation (SpO₂) ≥92%;\n9. . Female subjects of childbearing potential must have a negative urine pregnancy test and agree to use effective contraception during the trial until 1 year after infusion.\n\nPolyarticular Juvenile Idiopathic Arthritis (pJIA):\n\n1. . Onset before age 16, disease duration ≥6 weeks, diagnosed as polyarticular JIA according to the 2001 International League of Associations for Rheumatology (ILAR) classification criteria, and positive for rheumatoid factor (RF) and\u002For anti-citrullinated peptide\u002Fprotein antibody (ACPA): positive on ≥2 occasions at least 3 months apart during the first 6 months of illness;\n2. . Judged by the investigator to have active disease despite adequate standard-dose treatment prior to screening, meeting the following adequacy of treatment conditions: a. Treatment with conventional disease-modifying antirheumatic drugs (DMARDs) for at least 6 months, with stable doses of 2 DMARDs for ≥12 weeks; b. Treatment with at least 2 biologic agents, with stable doses for ≥12 weeks;\n3. . Juvenile Arthritis Disease Activity Score-27 (JADAS-27) \\>8.5;\n4. . Must have at least 5 active joints (defined as the presence of joint swelling; or in the absence of swelling, the presence of limited range of motion accompanied by pain on motion and\u002For tenderness) as per the American College of Rheumatology (ACR) definition at both screening and baseline;\n5. . No occurrence of macrophage activation syndrome within 1 month prior to screening.\n\nSjögren's Syndrome (SS):\n\n1. . Diagnosed with childhood-onset primary SS at least 24 weeks prior to signing the ICF, according to the 2002 American-European Consensus Group (AECG) classification criteria \u002F 2016 EULAR\u002FACR classification criteria and the 2021 Japanese classification criteria for childhood primary SS;\n2. . Meet the classification criteria for SS, and Intolerance or inadequate response to glucocorticoids (prednisone 1-2 mg\u002Fkg\u002Fday or equivalent doses of other corticosteroids) and at least 2 immunosuppressants, with a duration of glucocorticoid treatment of at least 6 months;\n3. . EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI) score ≥5 in at least 1 of the following 8 domains at screening: constitutional, lymphadenopathy, glandular, articular, cutaneous, renal, hematological, and serological;\n4. . EULAR Sjögren's Syndrome Patient Reported Index (ESSPRI) score ≥5 at screening;\n5. . Positive for anti-SSA\u002FRo antibody.\n\n   Juvenile Dermatomyositis (JDM):\n6. . Diagnosed with JDM at least 24 weeks prior to signing the ICF according to the 2017 EULAR\u002FACR classification criteria;\n7. . Meet the classification criteria for Refractory JDM (RJDM), and had Intolerance or inadequate response to glucocorticoids (prednisone 1-2 mg\u002Fkg\u002Fday or equivalent doses of other corticosteroids) and at least 2 immunosuppressants, with a duration of glucocorticoid treatment of at least 6 months;\n8. . Patients with anti-synthetase syndrome who are anti-synthetase antibody positive and meet the criteria for RJDM can be directly enrolled;\n9. . Patients with immune-mediated necrotizing myopathy who are signal recognition particle (SRP) or 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR) antibody positive and meet the criteria for RJDM can be directly enrolled.\n\nSystemic Sclerosis (SSc):\n\n1. . Meet the 2013 ACR\u002FEULAR classification criteria for SSc, with first non-Raynaud's phenomenon occurring at age \\\u003C18 years and disease duration ≤60 months;\n2. . Positive for antinuclear antibody (ANA) or any SSc-specific antibody;\n3. . Modified Rodnan Skin Score (mRSS) ≥15 (total score 51);\n4. . Meet the definition of treatment-refractory disease: inadequate response to glucocorticoids (≥0.5 mg\u002Fkg\u002Fday) and cyclophosphamide and at least 1 other immunomodulatory drug for over 3 months;\n5. . Diagnosed with refractory UCTD-ILD: UCTD typically refers to patients with symptoms and signs suggestive of CTD and serologic evidence of autoimmunity, but not fulfilling classification criteria for any defined CTD. Presence of ILD-related clinical manifestations: e.g., dry cough, exertional dyspnea, bibasral crackles, clubbing, OR chest high-resolution CT consistent with ILD features (often symmetric, subpleural), OR pulmonary function tests showing impaired diffusion capacity and restrictive ventilatory defect. All patients must have no improvement in symptoms like dyspnea or cough after at least 1 month of glucocorticoid therapy (prednisone ≥1 mg\u002Fkg\u002Fday or equivalent).\n\nSystemic Lupus Erythematosus (SLE):\n\n(1. Diagnosed with childhood-onset SLE according to the 2012 Systemic Lupus International Collaborating Clinics (SLICC) or 2019 EULAR\u002FACR classification criteria for SLE; (2). Must meet one of the following adequacy of treatment conditions:\n\n* After treatment with glucocorticoids (≥1 mg\u002Fkg\u002Fday prednisone or equivalent) and one or more immunomodulators (including cyclophosphamide, MMF, azathioprine, methotrexate, cyclosporine, tacrolimus, sirolimus, leflunomide, telitacicept, belimumab, and rituximab) for 3 months (3M);\n* Patients intolerant to conventional therapy may be considered for enrollment after the investigator judges benefit outweighs risk and with full informed consent from the patient\u002Fguardian;\n* OR inability to taper glucocorticoids to ≤5 mg\u002Fday after 6 months (6M) of conventional therapy; (3). Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) score \\>6; (4). No occurrence of macrophage activation syndrome within 1 month prior to screening.\n\nMixed Connective Tissue Disease (MCTD):\n\n(5). Diagnosed with childhood-onset primary MCTD at least 24 weeks prior to signing the ICF according to the Sharp 1986 MCTD classification criteria adapted for children; (6). Meet the above childhood MCTD classification criteria, and also had Intolerance or inadequate response to glucocorticoids (prednisone 1-2 mg\u002Fkg\u002Fday or equivalent doses of other corticosteroids) and at least 2 conventional immunosuppressants, with a duration of standardized glucocorticoid treatment of at least 6 months; (7). Childhood version of the Mixed Connective Tissue Disease Activity Index (MDAI) score ≥8 at screening; (8). Patient-reported outcome (PRO) score for MCTD characteristic involvement dimensions ≥5 at screening; (9). High-titer positive for anti-U1-RNP antibody (titer ≥1:1000), and negative for anti-Sm antibody.\n\nExclusion Criteria:\n\n1. . History of malignancy (except for basal cell or squamous cell skin cancer or carcinoma in situof the cervix that has been excised and cured for at least 5 years), or current malignancy.\n2. . Known allergy, hypersensitivity, intolerance, or contraindication to CD19\u002FBCMA CAR-NK cells or any component of the drugs that may be used in the study (including fludarabine, cyclophosphamide, and tocilizumab), or subjects who have experienced a severe allergic reaction in the past.\n3. . Evidence of severe active viral or bacterial infection, or uncontrolled systemic fungal infection at screening or baseline visits, or subjects with active or uncontrolled infection requiring parenteral antimicrobial therapy.\n4. . Subjects with cardiac insufficiency classified as Class III or IV according to the New York Heart Association (NYHA) functional classification (see Appendix).\n5. . Subjects with congenital heart disease, or history of acute myocardial infarction within 6 months prior to screening, or severe arrhythmia (including multifrequent ventricular premature beats, supraventricular tachycardia, ventricular tachycardia, etc.); or combined with moderate to large pericardial effusion, severe myocarditis, etc.; or unstable vital signs requiring vasopressors to maintain blood pressure.\n6. . Positive hepatitis B surface antigen (HBsAg) or hepatitis B core antibody (HBcAb) with detectable hepatitis B virus (HBV) DNA levels above the normal reference range in peripheral blood at screening; OR positive hepatitis C virus (HCV) antibody with detectable HCV RNA levels above the normal reference range; OR positive human immunodeficiency virus (HIV) antibody; OR positive syphilis test; OR positive cytomegalovirus (CMV) DNA test.\n7. . History of severe herpes infection, such as herpes encephalitis, ocular herpes, or disseminated herpes; signs of herpes or varicella-zoster virus infection (particularly varicella, herpes zoster) within 12 weeks prior to screening.\n8. . Current active tuberculosis or history of active tuberculosis, or subjects whose interferon-gamma release assay for tuberculosis infection cannot yield a negative result during the screening period.\n9. . Subjects with interstitial lung disease (ILD), meeting any of the following conditions are excluded: Forced vital capacity (FVC) \\\u003C50% of predicted value at screening, OR diffusing capacity of the lungs for carbon monoxide (DLCO) \\\u003C40% of predicted value; Requiring long-term oxygen therapy or non-invasive ventilation; Acute exacerbation of interstitial pneumonia\u002Facute respiratory failure within the past 6 months, or hospitalization due to ILD requiring intravenous pulse corticosteroid therapy; Rapidly progressive ILD as judged by the investigator.\n10. . Subjects with pulmonary arterial hypertension (PAH), meeting any of the following conditions are excluded: Results from right heart catheterization or echocardiography (non-invasive estimation) meeting any of the following: a. Estimated systolic pulmonary artery pressure (sPAP) \\>50 mmHg (assessed in conjunction with tricuspid regurgitation velocity); b. Diagnosis of WHO functional class III or IV PAH.\n\n    Hospitalization within the past 6 months due to acute exacerbation of PAH or right heart failure; Requiring intravenous prostacyclin analog therapy during the screening period; Presence of signs of right ventricular dysfunction, including but not limited to ascites, hepatic congestion, peripheral edema, accompanied by significantly elevated BNP\u002FNT-proBNP levels and clinically unstable symptoms.\n11. . History of epilepsy or other active central nervous system diseases.\n12. . Subjects with acquired or congenital immunodeficiency diseases.\n13. . History of any clinically significant cardiac, endocrine, hematological, hepatic, immunological, metabolic, urological, pulmonary, neurological, dermatological, psychiatric, renal disease, or other major condition that, in the investigator's judgment, precludes the administration of KN5601.\n14. . Solid organ or hematopoietic stem cell transplantation within 3 months prior to screening; OR acute graft-versus-host disease (GVHD) of grade 2 or higher within 2 weeks prior to screening.\n15. . Vaccination with a live vaccine within 4 weeks prior to screening.\n16. . Having received the following treatments within the specified time frames prior to the baseline visit: B cell depletion therapy within 26 weeks; Within 24 weeks prior to randomization: Anti-CD40 monoclonal antibody, belimumab, abatacept, anti-tumor necrosis factor alpha (anti-TNFα) biologics, immunoglobulin, plasmapheresis; Within 12 weeks prior to randomization: JAK inhibitors or other kinase inhibitors, unless explicitly permitted by the protocol; Use of traditional Chinese medicines, proprietary Chinese medicines, or health products containing Tripterygium wilfordii(Lei Gong Teng), Tripterygium hypoglaucum(Kunming Shan Hai Tang), Colquhounia coccineavar. mollis(Huo Ba Hua Gen), or white peony root (Paeonia lactiflora, Bai Shao) within 4 weeks; Within 3 half-lives of prior therapy, OR within 4 weeks, OR until the expected pharmacodynamic effects have returned to baseline levels (whichever is longer); B cell count below the lower limit of normal or baseline value (whichever is lower) following prior B cell depletion therapy.\n17. . Participation in any clinical trial within three months.\n18. . Any other condition that, in the opinion of the investigator, may increase the risk to the subject or interfere with the trial results.","5 Years",{"count":157,"type":20},36,[159],"EARLY_PHASE1","A single arm, open-label pilot study is designed to determine the safety and effectiveness of anti-CD19\u002FBCMA CAR-NK cell injection in patients with refractory pediatric rheumatic diseases.",[24,162,163,164],"Pediatric Rheumatological Condition (i.e., Arthritis, SLE, Kawasaki's Disaese)","Systemic Lupus Erythematosus (SLE)","Connective Tissue Disease-associated Interstitial Lung Disease","2026-03-18",{"date":167,"type":37},"2026-03-24",{"date":169,"type":20},"2026-03-19",{"date":171,"type":20},"2027-12-19",{"name":173,"class":90},"The Children's Hospital of Zhejiang University School of Medicine",{"id":175,"slug":176,"hasResults":11,"nctId":177,"briefTitle":178,"officialTitle":178,"acronym":4,"eligibilityCriteria":179,"healthyVolunteers":52,"sex":15,"minAge":16,"maxAge":180,"enrollmentInfo":181,"targetDuration":183,"studyType":21,"phases":4,"briefSummary":184,"conditions":185,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":205,"lastUpdatePostDateStruct":206,"startDateStruct":208,"completionDateStruct":210,"leadSponsor":212,"locationsCount":43},"100393366","rheumatology-patient-registry-and-biorepository-100393366","NCT04402086","Rheumatology Patient Registry and Biorepository","Inclusion Criteria for Rheumatology Patients:\n\n* Patients ≥18 years old with a diagnosis of a rheumatic autoimmune disease including, but not limited to: adult onset Still's disease, ankylosing spondylitis, antiphospholipid syndrome, Behcet's disease, dermatomyositis, giant cell arteritis, mixed connective tissue disease, polymyalgia rheumatica, polymyositis, psoriatic arthritis, reactive arthritis, rheumatoid arthritis, sarcoidosis, scleroderma, Sjogren's syndrome, systemic lupus erythematosus, undifferentiated connective tissue disease and vasculitis.\n* Receiving clinical care at Yale Rheumatology clinics\n\nExclusion Criteria for Rheumatology Patients:\n\n* Unable to provide informed consent\n* No patients will be excluded based on gender or ethnicity or pregnancy status.\n* Women who are currently pregnant will need to wait to donate a skin biopsy until after they deliver.\n* Patients allergic to lidocaine or epinephrine or have a history of impaired wound healing will not be able to donate a skin biopsy.\n\nInclusion Criteria for Healthy Volunteers:\n\n* Age ≥ 18 years old\n* No chronic skin conditions\n* No diagnosis of a rheumatic autoimmune disease (e.g., lupus, rheumatoid arthritis)\n* Normal BMI\n\nExclusion Criteria for Healthy Volunteers:\n\n* Unable to provide informed consent.\n* Currently pregnant or nursing unless the study goal is to study pregnant or nursing woman.\n* Allergies to lidocaine or epinephrine (skin biopsies).\n* A history of impaired wound healing (skin biopsies).","99 Years",{"count":182,"type":20},5000,"10 Years","To facilitate clinical, basic science, and translational research projects involving the study of rheumatic diseases.",[24,186,187,188,189,190,191,192,193,194,195,196,197,198,199,200,201,202,203,204],"Adult Onset Still Disease","Ankylosing Spondylitis","Psoriatic Arthritis","Reactive Arthritis","Antiphospholipid Syndrome","Systemic Lupus Erythematosus","Behcet Disease","Dermatomyositis","Polymyositis","Giant Cell Arteritis","Lyme Disease","Mixed Connective Tissue Disease","Polymyalgia Rheumatica","Rheumatoid Arthritis","Sarcoidosis","Systemic Sclerosis","Scleroderma","Sjogren's Syndrome","Undifferentiated Connective Tissue Diseases","2026-02-11",{"date":207,"type":37},"2026-02-13",{"date":209,"type":37},"2020-08-04",{"date":211,"type":20},"2030-06-01",{"name":213,"class":90},"Yale University",{"id":215,"slug":216,"hasResults":11,"nctId":217,"briefTitle":218,"officialTitle":219,"acronym":4,"eligibilityCriteria":220,"healthyVolunteers":11,"sex":15,"minAge":4,"maxAge":16,"enrollmentInfo":221,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":223,"conditions":224,"keywords":226,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":232,"lastUpdatePostDateStruct":233,"startDateStruct":235,"completionDateStruct":237,"leadSponsor":239,"locationsCount":241},"100619882","exploring-and-measuring-the-impact-of-steroids-in-children-and-young-people-100619882","NCT07350395","Exploring and Measuring the Impact of Steroids in Children and Young People","Assessing the Impact of Glucocorticoids in Children and Young People With Rheumatic Conditions, to Develop a Patient Reported Outcome Measure (PROM).","Inclusion Criteria:\n\n* 1\\. Rheumatology patients aged 0 to18 years old. 2. Patients should have capacity to assent or consent immediately prior to the interview.\n\n  3\\. The patient should have a good understanding of spoken and written English be able to understand the participant information sheets, assent\u002Fconsent forms.\n\n  4\\. Treatment with glucocorticoids with intravenous or oral glucocorticoids for an autoimmune or inflammatory condition within the previous two years (or longer duration).\n\nParents\u002Fguardians:\n\n1. Parents (mother\u002F father) or legal guardians of rheumatological patients fulfilling criteria 1-4 above.\n2. Parents or legal guardians should have capacity to consent for themselves (+\u002F- their child) immediately prior to the interview.\n3. The parents or legal guardians should have a good understanding of spoken and written English be able to understand the participant information sheets, assent\u002Fconsent forms.\n\nExclusion Criteria:\n\n* 1\\. Rheumatology patients who are more than 18 years of age. 2. Patients who do not have capacity to assent or consent immediately prior to the interview.\n\n  3\\. Patient who have insufficient understanding of spoken and written English be able to understand the participant information sheets, assent\u002Fconsent forms.\n\n  4\\. Patients who either have never taken steroids or have not taken steroids within the last two years as part of their treatment plan for their rheumatological condition.\n\n  5\\. Relative is not a parent or legal guardian. 6. Parents\u002Fguardians of rheumatology patients fulfilling any of the exclusion criteria above.\n\n  7\\. Parents\u002Fguardians who do not have capacity to assent or consent immediately prior to the interview.\n\n  8\\. Parents\u002Fguardians who have insufficient understanding of spoken and written English be able to understand the participant information sheets, assent\u002Fconsent forms.\n\n  9\\. Parents\u002Fguardians of rheumatology patients who have never taken steroids or have not taken steroids within the last two years as part of their treatment plan for their rheumatological condition.\n\n  10\\. Membership of the steering committee",{"count":222,"type":20},70,"Assessing the impact of glucocorticoids in children and young people with rheumatic conditions, to develop a patient reported outcome measure (PROM).\n\nGlucocorticoids, also known as steroids, are a very effective medication for the treatment of rheumatological conditions. They are used to reduce inflammation, pain and damage to organs. However, steroids can have some unwanted side effects, such as, increased weight, skin changes, feeling anxious, delayed puberty, diabetes and loss of bone mass. These side effects can therefore impact children and young people's health related quality of life (HRQoL).\n\nThe investigators would like to create a new questionnaire for children and young people (CYP) who take steroids due to their rheumatological condition. The questionnaire, called a Patient Reported Outcome Measure, (PROM), will measure how steroids are affecting CYP. The first step in creating the questionnaire is to talk to children, young people and their parents\u002Fguardians about their experiences of taking steroids. The investigators plan to do this in focus groups, with people around the same age. The second step will then be to take everything people said in the focus group to create the questions in the questionnaire. Cognitive interviewing will then be used in a structured one on one interview to test for relevance, clarity and understanding of the questions.\n\nChildren, young people and their parents\u002Fguardians will be involved throughout the research. Children and young people will give their thoughts and feedback on resources created for participants (consent forms\u002Fassent forms\u002Fparticipation information sheet\u002Finterview schedule), as well as how the focus groups and cognitive interviews should be structured.\n\nWith consent, participants will be provided with a lay summary of the results. Results will also be published within peer-reviewed journals, special interest groups, trial meetings, patient charity meetings and presented at conferences.",[24,133,225],"Rheumatologic Conditions (JRA,Lupus)",[227,228,229,230,231],"rheumatic diseases","children and young people","steroids","glucocorticoids","qualitative","2026-01-13",{"date":234,"type":37},"2026-01-20",{"date":236,"type":37},"2025-11-01",{"date":238,"type":20},"2026-12-31",{"name":240,"class":90},"University of the West of England",3,{"id":243,"slug":244,"hasResults":11,"nctId":245,"briefTitle":246,"officialTitle":247,"acronym":4,"eligibilityCriteria":248,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":249,"enrollmentInfo":250,"targetDuration":4,"studyType":56,"phases":251,"briefSummary":252,"conditions":253,"keywords":255,"overallStatus":80,"whyStopped":4,"lastUpdateSubmitDate":260,"lastUpdatePostDateStruct":261,"startDateStruct":263,"completionDateStruct":265,"leadSponsor":267,"locationsCount":43},"100614017","pain-neuroscience-education-and-vagus-nerve-stimulation-on-recovery-in-individuals-with-rheumatoid-arthritis-100614017","NCT07274124","Pain Neuroscience Education and Vagus Nerve Stimulation on Recovery in Individuals With Rheumatoid Arthritis","Comparison of the Effects of Pain Neuroscience Education and Vagus Nerve Stimulation on Recovery in Individuals With Rheumatoid Arthritis","Inclusion Criteria:\n\n* Individuals who were diagnosed with RA at least one year ago,\n* Ages of 18 and 65,\n* Have been experiencing pain for three months or more,\n* Score 24 or higher on the Mini Mental State Examination (MMSE), and can follow instructions will be included in the study.\n\nExclusion Criteria:\n\n* Individuals under 18 years of age,\n* Reporting acute pain or pain from injury,\n* Having a history of surgery within the last year,\n* Having a score of \\\u003C24 on the MMSE,\n* Having any of the cerebrovascular disease, cardiovascular disease, symptomatic coronary artery disease, myocardial infarction, congestive heart failure, or uncontrolled hyper\u002Fhypotension,\n* History of vagotomy surgery, or having an implanted electrical\u002Fneurostimulator device will not be included in the study.","65 Years",{"count":157,"type":20},[58],"In the context of this randomized controlled study, patients who are diagnosed with Rheumatoid arthritis in Cerrahpaşa Faculty of Medicine Hospital, will be taken into a rehabilitation program by a qualified physiotherapist to improve their pain, pain perception, inflammatory markers and quality of life, with one of the pain neuroscience education, vagal nerve stimulation and traditional exercise interventions. The results of each intervention method will be analyzed and compared at the end of the 8 weeks study protocol.",[24,254],"Rheumatoid Arthritis (RA)",[256,257,258,259],"rheumatoid arthritis","pain neuroscience education","vagal nerve stimulation","exercise","2025-11-27",{"date":262,"type":37},"2025-12-10",{"date":264,"type":20},"2026-01",{"date":266,"type":20},"2027-07",{"name":268,"class":90},"Medipol University",{"id":270,"slug":271,"hasResults":11,"nctId":272,"briefTitle":273,"officialTitle":274,"acronym":4,"eligibilityCriteria":275,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":276,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":278,"conditions":279,"keywords":4,"overallStatus":80,"whyStopped":4,"lastUpdateSubmitDate":280,"lastUpdatePostDateStruct":281,"startDateStruct":283,"completionDateStruct":285,"leadSponsor":287,"locationsCount":4},"100604413","accuracy-of-cbc-derived-markers-against-crp-and-esr-in-detecting-active-rheumatoid-arthritis-in-upper-egypt-100604413","NCT07149194","Accuracy of CBC Derived Markers Against CRP and ESR in Detecting Active Rheumatoid Arthritis in Upper Egypt","Assessment of the Accuracy of CBC-Derived Markers Against CRP and ESR in Detecting Active Rheumatoid Arthritis in Upper Egypt\"","Inclusion Criteria:\n\n* 1-Adults aged ≥18 years. 2-Established RA diagnosis according to ACR\u002FEULAR criteria {ACR: American College of Rheumatology, a professional organization of rheumatologists.\n\nEULAR: European League Against Rheumatism, a European organization for rheumatology.\n\n3-Willing to provide informed consent\n\nExclusion Criteria:\n\n* 1-Presence of infection, malignancy, or other autoimmune diseases. 2-Recent use (within 4 weeks) of corticosteroids or immunosuppressive therapy. 3-Pregnant or lactating women.",{"count":277,"type":20},150,"Rheumatoid arthritis (RA) is a chronic autoimmune disease that leads to persistent synovial inflammation, joint destruction, and disability, often with extra-articular manifestations like interstitial pneumonia. It predominantly affects middle-aged individuals, especially women. Early diagnosis and accurate disease activity assessment are crucial to prevent irreversible joint damage and systemic complications (4).\n\nClinical tools like the Disease Activity Score in 28 joints (DAS28) are commonly used to monitor RA, relying on inflammatory markers such as C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR). However, CRP and ESR can be influenced by factors unrelated to RA, such as infections or anemia, and may not always be available or cost-effective in resource-limited settings (1).\n\nIn recent years, complete blood count (CBC)-derived markers have emerged as affordable and accessible alternatives for assessing systemic inflammation. These include the neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), lymphocyte-to-monocyte ratio (LMR), and red cell distribution width (RDW). These indices have shown strong correlations with RA disease activity in various studies, particularly NLR and RDW, which have high sensitivity and specificity for detecting active disease (2-3).\n\nStudies in Egypt have explored the diagnostic accuracy of CBC-derived markers and composite indices like the CRP-to-albumin ratio (CAR) and albumin-to-fibrinogen ratio (AFR). These markers correlate significantly with DAS28 scores, suggesting they may be reliable indicators of RA disease activity in Egyptian patients (1-3).",[24],"2025-08-24",{"date":282,"type":37},"2025-08-29",{"date":284,"type":20},"2025-09-01",{"date":286,"type":20},"2027-10-01",{"name":288,"class":90},"Assiut University",{"id":290,"slug":291,"hasResults":11,"nctId":292,"briefTitle":293,"officialTitle":294,"acronym":295,"eligibilityCriteria":296,"healthyVolunteers":52,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":297,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":299,"conditions":300,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":280,"lastUpdatePostDateStruct":311,"startDateStruct":313,"completionDateStruct":315,"leadSponsor":317,"locationsCount":43},"100604475","clinical-assessment-for-rheumatologic-disease---research-and-advancement-in-safety-and-efficacy-100604475","NCT07150000","Clinical Assessment for Rheumatologic Disease - Research and Advancement in Safety and Efficacy","CARe RAiSE Study - Clinical Assessment for Rheumatologic Disease - Research and Advancement in Safety and Efficacy","CARe RAiSE","Inclusion Criteria:\n\n* Participants aged ≥ 18 years\n* Signed written informed consent to participate voluntarily in the study.\n* Confirmed diagnosis (by the treating physician) of one of the following autoimmune or autoinflammatory rheumatic diseases:\n* Rheumatoid arthritis (RA)\n* Psoriatic arthritis (PsA)\n* Axial spondyloarthritis (axSpA)\n* Giant cell arteritis (GCA)\n* Connective tissue diseases, including:\n\n  1. Systemic lupus erythematosus (SLE)\n  2. Systemic sclerosis (SSc)\n  3. Mixed connective tissue disease (MCTD)\n  4. Idiopathic inflammatory myopathies (IIM)\n* ANCA-associated vasculitides (AAV), including:\n\n  1. Microscopic polyangiitis (MPA)\n  2. Granulomatosis with polyangiitis (GPA)\n  3. Eosinophilic granulomatosis with polyangiitis (EGPA)\n* Autoinflammatory diseases, including\n\n  1. Familial Mediterranean fever (FMF)\n  2. Cryopyrin-associated periodic syndromes (CAPS)\n  3. TNF receptor-associated periodic syndrome (TRAPS)\n  4. Adult-onset Still's disease (AOSD)\n\n     Exclusion Criteria:\n* Refusal to participate in the study or inability to provide informed consent.\n\nInclusion Criteria - Healthy Control Group:\n\n* Participants aged ≥ 18 years (capable of providing informed consent).\n* Signed written informed consent to participate voluntarily in the study.\n\nExclusion Criteria - Healthy Control Group:\n\n\\- Presence of a known or active rheumatologic disease.",{"count":298,"type":20},120,"The CARe RAiSE project represents a pioneering translational initiative aimed at advancing precision medicine in the treatment of autoimmune rheumatic diseases. The primary objective is the development and implementation of an innovative cell-based ex vivo assay that enables individualized prediction of therapeutic response to disease-modifying antirheumatic drugs (DMARDs). By identifying the most effective treatment option for each patient, this approach seeks to enhance therapeutic efficacy, reduce time to clinical response, and minimize healthcare costs.\n\nDespite the availability of numerous DMARDs, clinical decision-making remains largely empirical due to considerable interindividual variability in treatment response. This frequently results in a prolonged trial-and-error process, placing a significant burden on patients and the healthcare system. CARe RAiSE aims to overcome this limitation by providing a functional diagnostic tool that can predict a patient's immunological response to specific DMARDs prior to treatment initiation.\n\nThe assay is based on peripheral blood mononuclear cells (PBMCs) obtained from individual patients, enabling a physiologically relevant assessment of immune responsiveness to targeted therapies. Combining high-content imaging with homogeneous well-based cytokine and inflammasome activity assays, the platform allows for a detailed single-cell analysis of inflammatory pathways. These data are used to generate predictive signatures of treatment response, thereby facilitating a mechanistically informed and personalized therapeutic strategy.\n\nThrough this approach, CARe RAiSE introduces a scientifically grounded, efficient, and patient-specific method for DMARD selection, with the potential to substantially improve patient outcomes and reduce the socioeconomic impact of autoimmune rheumatic diseases.",[24,254,301,302,303,304,305,306,307,103,308,309,310],"Giant Cell Arteritis (GCA)","Psoriatic Arthritis (PsA)","Axial Spondylarthritis (axSpA)","Polymyalgia Rheumatica (PMR)","ANCA Associated Vasculitis (AAV)","Connective Tissue Disease (CTD)","Systemic Sclerosis (SSc)","Idiopathic Inflammatory Myopathy (IIM)","Autoinflammatory Disease","Gout Arthritis",{"date":312,"type":37},"2025-09-02",{"date":314,"type":37},"2025-04-01",{"date":316,"type":20},"2028-12",{"name":318,"class":90},"University of Bonn",{"id":320,"slug":321,"hasResults":11,"nctId":322,"briefTitle":323,"officialTitle":324,"acronym":325,"eligibilityCriteria":326,"healthyVolunteers":52,"sex":15,"minAge":16,"maxAge":327,"enrollmentInfo":328,"targetDuration":4,"studyType":56,"phases":329,"briefSummary":332,"conditions":333,"keywords":339,"overallStatus":80,"whyStopped":4,"lastUpdateSubmitDate":345,"lastUpdatePostDateStruct":346,"startDateStruct":348,"completionDateStruct":350,"leadSponsor":352,"locationsCount":43},"100598966","phase-1-clinical-trial-phase-iiia-to-evaluate-the-safety-and-immunogenicity-of-streptincor-100598966","NCT07078357","Clinical Trial Phase I\u002FIIa to Evaluate the Safety and Immunogenicity of StreptInCor","Phase I\u002FIIa Clinical Trial to Evaluate the Safety and Immunogenicity of StreptInCor, a Synthetic Vaccine Against Streptococcus Pyogenes, in Healthy Adult Volunteers.","StreptInCorVac","Inclusion Criteria:\n\n* • Healthy male or female volunteers, aged between 18 and 45 years;\n\n  * Availability to undergo all procedures throughout the study period;\n  * Provide free and informed consent to participate in the study.\n\nExclusion Criteria:\n\n* Participation in clinical trials within the last year\n* Participation in cohort studies\n* Diagnosis of concomitant infections or diseases that may affect immunity, including active HIV infection, hepatitis B, hepatitis C, diabetes mellitus, neoplasms, and autoimmune diseases;\n* Current or previous diagnosis or family history of ARF, chorea, obsessive-compulsive disorder, or glomerulonephritis;\n* Current or previous diagnosis of heart diseases;\n* Severe asthma or chronic obstructive pulmonary disease (COPD);\n* Abnormal neurological clinical assessment, especially chorea;\n* Use of treatments that may affect immunity in the last four weeks, including immunomodulators, corticosteroids (only systemic use for two weeks or more), or antineoplastic agents;\n* Use of treatments that may affect heart valves in the last four weeks or planned during the study period, including fenfluramine and dexfenfluramine;\n* Renal insufficiency determined by estimated creatinine clearance below 45 ml\u002Fmin\u002F1.73m²;\n* History of intolerance or allergy to any component of the study product, including antigen or adjuvant;\n* Presence of valve abnormalities or alterations in cardiac anatomy as defined by echocardiogram;\n* Altered electrocardiogram;\n* Evidence or suspicion of recent S. pyogenes infection based on clinical symptoms in the last four weeks;\n* Pregnancy, breastfeeding mother, or intention to become pregnant during the study period (only female participants);\n* Any other condition that may interfere with the study process as assessed by the researchers, including sample size and statistical power.","45 Years",{"count":55,"type":20},[330,331],"PHASE1","PHASE2","This is a Phase I\u002FIIa, randomized, double-blind, placebo-controlled, dose-escalation clinical trial to test the candidate vaccine StreptInCor. The study will include four different doses (25 µg, 50 µg, 100 µg, and 200 µg) of StreptInCor produced under Good Manufacturing Practices (GMP) and formulated with aluminum hydroxide as the vaccine adjuvant. The adjuvant alone will be used as a placebo in this trial. Five groups, each consisting of twelve healthy adult volunteers, will randomly receive two doses of the vaccine or placebo with a 28-day interval, along with a booster dose six months after the initial vaccination",[334,335,336,24,337,338],"Rheumatic Heart Disease","Rheumatic Heart Disease in Children","Vaccine Adverse Reaction","Vaccine Acceptance","Vaccine",[340,341,342,343,344],"Acute rheumatic fever","Rheumatic heart disease","Vaccine development program","Group A streptococcus (GAS)","Streptococcus pyogenes","2025-07-17",{"date":347,"type":37},"2025-07-22",{"date":349,"type":20},"2025-10-01",{"date":351,"type":20},"2028-12-01",{"name":353,"class":90},"University of Sao Paulo General Hospital",{"id":355,"slug":356,"hasResults":11,"nctId":357,"briefTitle":358,"officialTitle":359,"acronym":360,"eligibilityCriteria":361,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":362,"enrollmentInfo":363,"targetDuration":4,"studyType":56,"phases":365,"briefSummary":366,"conditions":367,"keywords":369,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":371,"lastUpdatePostDateStruct":372,"startDateStruct":374,"completionDateStruct":376,"leadSponsor":378,"locationsCount":43},"100425218","evaluation-of-mood-disorders-under-biologics-in-chronic-inflammatory-rheumatic-disease-100425218","NCT04817072","Evaluation of Mood Disorders Under Biologics in Chronic Inflammatory Rheumatic Disease","Evaluation of Mood Disorders Under Biologics (Anti-TNF Alpha) in Chronic Inflammatory Rheumatic Disease","EMOTION","Inclusion Criteria:\n\n* Adult patients (≥18 ; ≤ 80)\n* Patient with rheumatoid arthritis (RA) according to the ACR 2010 criteria, axial or peripheral spondyloarthritis (SpA) according to ASAS criteria, ankylosing spondylitis (AS) according to the New York criteria or psoriatic arthritis (PsA) according to CASPAR criteria\n* Signature of informed consent\n* Affiliation to a French social security or receiving such a scheme\n\nExclusion Criteria:\n\n* Patient having previously received anti-TNFα treatment\n* Patient with previously diagnosed depressive or psychiatric pathology and \u002F or receiving anti-depressant treatment\n* Subjects with limited legal capacity.\n* Subjects judged by the investigator to be unlikely to comply with study procedures\n* Subjects with no social security coverage.\n* Pregnant women.\n* Subjects still in the exclusion period of another study, or according to the national registry of clinical trial participants.","80 Years",{"count":364,"type":20},108,[58],"Chronic inflammatory rheumatic diseases (CIRD) affect many organ systems. Painful sensations within the joints spine, hand and foot deformities, low quality of life and psychosocial status in patients with rheumatoid arthritis, spondyloarthritis and psoriatic arthritis can lead to the development of anxiety and depression. Prevalences of anxiety increase in patients suffering of CIRD, compared with healthy individuals. Another connection has been identified by the links between depression and systemic inflammation. It is proven that higher plasma levels of pro-inflammatory cytokines such as tumor necrosis factor alpha (TNFa) affect neurotransmitter metabolism, with influence on patients mood. The purpose of EMOTION study is therefore to analyze thymic variation under TNFa therapy, as treatment of CIRDs.",[24,368],"Mood Disorders",[370],"TNF alpha inhibitor","2025-07-04",{"date":373,"type":37},"2025-07-09",{"date":375,"type":37},"2021-05-19",{"date":377,"type":20},"2026-05",{"name":379,"class":90},"Centre Hospitalier Universitaire de Besancon",{"id":381,"slug":382,"hasResults":11,"nctId":383,"briefTitle":384,"officialTitle":385,"acronym":386,"eligibilityCriteria":387,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":388,"targetDuration":4,"studyType":56,"phases":390,"briefSummary":391,"conditions":392,"keywords":394,"overallStatus":80,"whyStopped":4,"lastUpdateSubmitDate":397,"lastUpdatePostDateStruct":398,"startDateStruct":399,"completionDateStruct":401,"leadSponsor":403,"locationsCount":43},"100594692","personalized-outreach-for-equitable-treatment-in-rheumatology-100594692","NCT07022756","Personalized Outreach for Equitable Treatment in Rheumatology","Personalized Outreach for Equitable Treatment in Rheumatology: A Randomized Controlled Trial of Patient Outreach and Honoraria in an Inner City Rheumatology Clinic","POET-Rheum","Inclusion Criteria:\n\n* Have a diagnosis of inflammatory arthritis secondary to an autoimmune rheumatic disease\n* Be attached to one of the Vancouver Coastal Health Community Health Centres for primary care\n* Be willing to attend in-person appointments at Pender Community Health Centre\n* Be at least 18 years of age and capable of consenting to participation\n* Be able to receive medical care in English.\n\nExclusion Criteria:\n\n* Have cognitive impairment or an untreated psychiatric condition that would severely impair ability to engage with outreach or treatment\n* Have no reasonably reliable method of contact (phone, email, social media, etc.)",{"count":389,"type":20},20,[58],"The primary goal of this study is to determine whether providing patient honoraria and\u002For outreach services can improve the attendance rate of appointments at an inner city rheumatology clinic in Vancouver, British Columbia.\n\nThe main question it aims to answer are:\n\n* Does providing a financial honorarium ($20 for each follow-up appointment with completed bloodwork) improve attendance rate at an inner city rheumatology clinic?\n* Does providing a personalized outreach service for rheumatic diseases improve attendance rate at an inner city rheumatology clinic?\n\nThe researchers will compare providing patient honoraria to providing both honoraria and outreach services, and compare each of these to the regular appointment schedule without honoraria or outreach.\n\nParticipants will:\n\n* Undergo randomization to receive honoraria or honoraria and outreach services together\n* Complete surveys about their health and understanding of their rheumatic disease at baseline, 3-month, and 6-month intervals\n* Visit the clinic every month for check-ups and monitoring bloodwork if they are started on immunosuppressants for their condition",[24,102,254,302,393],"Connective Tissue Disease",[395,102,396],"Rheumatology","Inner City Health","2025-07-01",{"date":371,"type":37},{"date":400,"type":20},"2025-07-02",{"date":402,"type":20},"2026-06",{"name":404,"class":90},"University of British Columbia",{"id":406,"slug":407,"hasResults":11,"nctId":408,"briefTitle":409,"officialTitle":410,"acronym":4,"eligibilityCriteria":411,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":412,"targetDuration":4,"studyType":56,"phases":414,"briefSummary":415,"conditions":416,"keywords":4,"overallStatus":80,"whyStopped":4,"lastUpdateSubmitDate":418,"lastUpdatePostDateStruct":419,"startDateStruct":421,"completionDateStruct":423,"leadSponsor":425,"locationsCount":241},"100596194","comparison-of-initial-treatment-for-carpal-tunnel-syndrome-related-to-rheumatic-diseases-corticosteroid-injection-versus-nighttime-splinting-100596194","NCT07042282","Comparison of Initial Treatment for Carpal Tunnel Syndrome Related to Rheumatic Diseases: Corticosteroid Injection Versus Nighttime Splinting","Comparison of Initial Treatment for Carpal Tunnel Syndrome Related to Rheumatic Diseases: Corticosteroid Injection Versus Nighttime Splinting - A Pragmatic, Open-Label, Multicenter, Randomized Clinical Trial","Inclusion Criteria:\n\n1. Patients aged no less than 18 years old with unilateral or bilateral carpal tunnel syndrome diagnosed by a specialist according to the Katz diagnostic criteria, and with at least one associated rheumatic disease;\n2. Patients have had symptoms of CTS for at least six weeks, and the side with more severe symptoms is designated as the target side for the study.\n3. During the current episode, the target side has not been treated.\n\nExclusion Criteria:\n\n1. Patients who have plan for surgical treatment on his or her CTS within the following 6 months;\n2. Received corticosteroid injections in the wrist within the past 6 months;\n3. Patients who are unable to wear a splint due to trauma or other reasons;\n4. Patients with clinical manifestations or electrophysiological changes indicative of significant axonal loss or denervation, including thenar muscle atrophy, sensory loss (two-point discrimination greater than 8 mm), absence of SNAP (sensory nerve action potential), absence of CMAP (compound muscle action potential) in the thenar muscles, etc.;\n5. Patients who require long-term use of any form of opioids.\n6. Patients who have used opioids (e.g., tramadol) or neuropathic pain medications (gabapentin, pregabalin, etc.) within the past 2 weeks;\n7. Patients who have received non-recommended wrist injection treatments (e.g., 5% glucose, platelet-rich plasma, ozone, chitosan, hyaluronic acid, etc.) within the past 6 months;\n8. Patients who have undergone non-recommended physical therapies (e.g., electrotherapy, magnetotherapy, laser therapy, etc.) within the past 6 months;\n9. Patients who are pregnant or plan to become pregnant within the next 6 months.",{"count":413,"type":20},248,[58],"The aim of this study is to evaluate the effects of corticosteroid injection verses nighttime splinting as initial treatments on wrist function, quality of life, and sleep quality in patients with rheumatoid disease-related carpal tunnel syndrome. Participants will be randomly assigned to two groups and will receive the following interventions: one group will wear a neutral position night splint for 6 weeks, and the other group will receive a single local injection of methylprednisolone 40 mg as the initial treatment. Follow-up evaluations will be conducted at 6, 12, and 18 weeks to assess wrist function, sleep quality, and quality of life, and to dynamically adjust the treatment plan.",[417,24],"Carpal Tunnel Syndrome (CTS)","2025-06-25",{"date":420,"type":37},"2025-06-29",{"date":422,"type":20},"2025-08-01",{"date":424,"type":20},"2027-08-01",{"name":426,"class":90},"Yun Qian",{"id":428,"slug":429,"hasResults":11,"nctId":430,"briefTitle":431,"officialTitle":431,"acronym":4,"eligibilityCriteria":432,"healthyVolunteers":52,"sex":433,"minAge":16,"maxAge":327,"enrollmentInfo":434,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":435,"conditions":436,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":442,"lastUpdatePostDateStruct":443,"startDateStruct":445,"completionDateStruct":447,"leadSponsor":449,"locationsCount":43},"100499667","patients-pregnant-women-with-or-without-primary-antiphospholipid-antibody-syndrome-100499667","NCT05786235","Patients Pregnant Women With or Without Primary Antiphospholipid Antibody Syndrome","Inclusion Criteria:\n\n* Group 1\n\n  1. Pregnant patients between the ages of 18 and 45 years.\n  2. Diagnosis of primary APS, according to international classification criteria.\n* Group 2\n\n  1. Pregnant patients between the ages of 18 and 45 years.\n  2. Patients with at least one previous full-term pregnancy.\n  3. No diagnosis of APS, according to international classification criteria.\n\nExclusion Criteria:\n\n* Group 1\n\n  1. PMA pregnancies.\n  2. Known chronic pathology in gestational period such as chronic essential hypertension, neurological pathology\n  3. Previous thrombotic event\n  4. Chronic renal failure not related to AD\n  5. Previous history of oncology\n* Group 2\n\n  1. Pregnancy by PMA.\n  2. Previous history of polyabortion and\u002For late pregnancy complications.\n  3. Known chronic pathology in gestational period such as chronic essential hypertension, neurological pathology\n  4. Previous thrombotic event\n  5. Previous history of oncology","FEMALE",{"count":55,"type":20},"The purpose of the study is to evaluate the ability of placental angiogenesis markers to predict the risk of PE in pregnancy in women with primary APS.\n\nTo construct reference intervals of placental angiogenesis markers specific to women affected by primary APS in pregnancy by measuring the levels of sFlt-1and PlGF in serum maternal serum and their sFlt-1\u002FPlGF ratio during the trimesters of gestation (I TM, II TM and III TM).\n\nFor this aim the study will involve recruiting two groups of subjects, one will be cases and one will be controls.",[437,438,439,440,441,24],"Preeclampsia","Immunologic Disease","Antiphospholipid Antibody Syndrome Primary","Pregnancy Complications","Pregnancy, High Risk","2025-06-17",{"date":444,"type":37},"2025-06-18",{"date":446,"type":37},"2022-12-06",{"date":448,"type":20},"2026-06-06",{"name":450,"class":90},"IRCCS San Raffaele",{"id":452,"slug":453,"hasResults":11,"nctId":454,"briefTitle":455,"officialTitle":456,"acronym":4,"eligibilityCriteria":457,"healthyVolunteers":11,"sex":433,"minAge":16,"maxAge":458,"enrollmentInfo":459,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":461,"conditions":462,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":442,"lastUpdatePostDateStruct":464,"startDateStruct":465,"completionDateStruct":467,"leadSponsor":469,"locationsCount":43},"100501284","medically-assisted-fertilization-techniques-in-systemic-immunoreumatologic-diseases-100501284","NCT05807256","Medically Assisted Fertilization Techniques in Systemic Immunoreumatologic Diseases","Assessment of Maternal-fetal Outcome in Pregnancy From Medically Assisted Fertilization Techniques in Women With Systemic Immunoreumatologic Diseases","Inclusion Criteria:\n\n* Patients diagnosed with systemic immunoreumatologic disease such as SLE, APS, RA, SpA, SclS, SS, PM-DM, vasculitis\n* patients who have performed one or more PMAs between January 2000 and April 2021\n* patients who had their last follow-up by February 2022\n\nExclusion Criteria:\n\n* Patients diagnosed with only one organ autoimmunity (e.g., diabetes mellitus I, thyroiditis of Hashimoto's, celiac disease or chronic inflammatory bowel disease in the absence of systemic disease associated);\n* patients with severe renal failure, significant pulmonary hypertension or cardiomyopathy severe.","50 Years",{"count":460,"type":20},500,"Systemic rheumatological diseases often occur in young women of childbearing age and can therefore impact fertility. There are diseases, such as arthritis, which present no contraindication to assisted reproductive techniques (ARTs), because there is no influence on the disease itself if the disease activity at conception is stable. On the other hand, patients suffering from connective tissue diseases, primarily Systemic Lupus Erythematosus (SLE) and patients suffering from primary or SLE-related Anti-Phospholipid Antibody Syndrome (APS), deserve more targeted therapies both in the context of ARTs and in the ensuing pregnancy.\n\nTo evaluate the response to ARTs in patients with systemic rheumatological diseases, both in terms of reactivation of the underlying pathology and in terms of ARTs outcome.",[24,463,441,440,438],"Fertility Disorders",{"date":444,"type":37},{"date":466,"type":37},"2022-05-04",{"date":468,"type":20},"2025-11-30",{"name":450,"class":90},{"id":471,"slug":472,"hasResults":11,"nctId":473,"briefTitle":474,"officialTitle":475,"acronym":476,"eligibilityCriteria":477,"healthyVolunteers":11,"sex":15,"minAge":249,"maxAge":4,"enrollmentInfo":478,"targetDuration":4,"studyType":56,"phases":480,"briefSummary":481,"conditions":482,"keywords":484,"overallStatus":80,"whyStopped":4,"lastUpdateSubmitDate":490,"lastUpdatePostDateStruct":491,"startDateStruct":493,"completionDateStruct":495,"leadSponsor":497,"locationsCount":43},"100593389","calcium-pyrophosphate-deposition-cppd-disease-100593389","NCT07005804","Calcium Pyrophosphate Deposition (CPPD) Disease","Calcium Pyrophosphate Deposition (CPPD) Disease : Clinical and Paraclinical Profile, Gene Expression and Metabolomics of the Acute and Chronic Clinical Phenotype","PYC-OMIC","Inclusion Criteria - Acute forms of CPPD: retrospective part of the study\n\n* Cases included in the COLCHICORT cohort (NCT03128905), for whom this was the first acute episode of CPPD\n\nInclusion Criteria - Chronical forms of CPPD : prospective part of the study\n\n* Patients affiliated to the French social security system\n* Age ≥ 65 years\n* Diagnosis of chronic CPPD (recurrent acute or persistent arthritis), meeting ACR\u002FEULAR 2023,11 classification criteria after evaluation by a rheumatologist in the rheumatology department\n* Progression of CPPD rheumatism for at least 3 months and still active CPPD rheumatism, defined by a visual analogue scale (VAS) of disease activity ≥ 40 and\u002For presentation of at least 1 crisis over the last 3 months\n* Glomerular Filtration Rate (GFR) in Chronic Kidney Disease Epidemiology (CKD EPI Collaboration) ≥ 30ml\u002Fmin\u002F1.73m2\n* Minimum time between the last intake of a crisis treatment and inclusion in the study, depending on their half-life, in order to not interfere with the results of the omics analyses: 2 weeks (Nonsteroidal Anti-Inflammatory Drugs Per Os (PO) or Intramuscular (IM) or Intravenous (IV); corticosteroids PO or IV; colchicine PO; anakinra Subcutaneous (SC), 1 month (methotrexate PO, tocilizumab SC), 3 months (canakinumab SC, tocilizumab IV)\n* Signed written consent for study participation\n\nExclusion Criteria - Acute forms of CPPD:\n\n* Missing data concerning transcriptomic and metabolomic analyses.\n* Opposition\n\nExclusion Criteria - For chronic forms of CPPD:\n\n* History of gout or presence of monosodium urate (MSU) crystals on joint fluid,\n* Cognitive decline (confusion and neurodegenerative diseases)\n* Inability to provide informed consent and disease VAS\n* Patient under guardianship or curatorship",{"count":479,"type":20},137,[58],"The goal of this clinical trial is to describe the transcriptomic and metabolomic profile of patients with chronic Calcium Pyrophosphate Deposition (CPPD) compared to those with acute CPPD.\n\nThe hypotheses are as follows :\n\n* It is hypothesised that there is a transcriptomic and metabolomic signature of CPPD which explains why therapeutic responses to different anti-inflammatory treatments differ from one phenotype to another one\n* It is hypothesised that the acute and chronic clinical phenotypes of CPPD have different clinical, biological and imaging characteristics, as well as a differing predisposition toward crystalline deposition and inflammatory pathway activation.\n\nThe management of participants with chronic forms of the disease included in this research was modelled on the usual recommended management, including a biological workup, joint puncture, ultrasound and radiographic workup. Double-energy CT scans and transcriptomic and metabolomic analyses on plasma are not routine tests.",[483,24],"Calcium Pyrophosphate Deposition Disease",[485,486,487,488,489],"Calcium pyrophosphate deposition disease","gene expression","acute clinical phenotype","chronic clinical phenotype","metabolic expression","2025-05-26",{"date":492,"type":37},"2025-06-05",{"date":494,"type":20},"2025-10",{"date":496,"type":20},"2027-11",{"name":498,"class":90},"Lille Catholic University",{"id":500,"slug":501,"hasResults":11,"nctId":502,"briefTitle":503,"officialTitle":504,"acronym":505,"eligibilityCriteria":506,"healthyVolunteers":52,"sex":15,"minAge":507,"maxAge":4,"enrollmentInfo":508,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":510,"conditions":511,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":518,"lastUpdatePostDateStruct":519,"startDateStruct":521,"completionDateStruct":523,"leadSponsor":525,"locationsCount":43},"100348214","observational-pharmaco-epidemiology-research--analysis-100348214","NCT03813862","Observational Pharmaco-Epidemiology Research & Analysis","OPERA Longitudinal Observational Database in the Study of Chronic Diseases, Treatments and Outcomes","OPERA","Inclusion Criteria:\n\n* Patients who are treated in the practices who enroll and participate in the study\n* Patients whose treatment is documented in the practice's electronic health record system\n\nExclusion Criteria:\n\n* Patients who opt out of OPERA","0 Years",{"count":509,"type":20},2000000,"Greater advances are needed in two separate but related areas in healthcare: 1) the Clinical Decision Support Systems that complement the EHR use in support of routine patient care, population management and disease management; and 2) the use of the point-of-care observational data from the provider-patient encounter that support realworld medical research and healthcare quality measure assessment. Real-world evaluations of treatments of chronic diseases in the context of comorbid conditions and special populations (minorities, women, mentally ill, and those with addiction) are limited. The purpose of the OPERA database is to help address this unmet need in clinical research.",[512,513,514,515,516,24,517],"Chronic Disease","HIV\u002FAIDS","Liver Diseases","Inflammatory Bowel Diseases","Cardiovascular Diseases","Neurodegenerative Diseases","2025-02-24",{"date":520,"type":37},"2025-02-25",{"date":522,"type":37},"2013-12-01",{"date":524,"type":20},"2035-11",{"name":526,"class":527},"Epividian","INDUSTRY",{"id":529,"slug":530,"hasResults":11,"nctId":531,"briefTitle":532,"officialTitle":533,"acronym":4,"eligibilityCriteria":534,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":362,"enrollmentInfo":535,"targetDuration":4,"studyType":56,"phases":536,"briefSummary":537,"conditions":538,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":540,"lastUpdatePostDateStruct":541,"startDateStruct":543,"completionDateStruct":545,"leadSponsor":546,"locationsCount":43},"100430853","tdcs-in-post-acute-covid-19-patients-with-sards-100430853","NCT04890483","tDCS in Post-Acute COVID-19 Patients With SARDs","Transcranial Direct Current Stimulation in Post-Acute COVID-19 Patients With Systemic Autoimmune Rheumatic Diseases","Inclusion Criteria:\n\n* Patients with well-defined ARDs (rheumatoid arthritis, sclerosis systemic, Sjögren syndrome, spondyloarthritis, systemic lupus erythematosus, systemic vasculitis, and systemic autoimmune myopathies)\n* Fatigue or general pains.\n\nExclusion Criteria:\n\n* Neoplasia, using heart pacemarker, using visceral metalic clips, infections (HIV, HTLV-1, hepatitis), pregnance, previous historical of convulsions or epilepsies",{"count":389,"type":20},[58],"Some patients develop \"Post-acute COVID-19 syndrome,\" in which they experience persistent symptoms after recovering from the acute phase of COVID-19 infection. This syndrome may be more significant in patients with systemic autoimmune rheumatic diseases (SARDs) who have been suffering from several symptoms associated to SARDs, such as myalgia, fatigue, and general pains.\n\nThe transcranial direct current stimulation (tDCS) technique has been frequent, for example, to relieve fatigue and general pains in general population. However, to date, there are no studies evaluating this technique in ARD patients with post-acute COVID-19; therefore, the main objective of the opened study is to evaluate the safety and efficacy of the application of acute tDCS in ARD patients with post-acute COVID-19.",[24,539],"Autoimmune Diseases","2024-12-04",{"date":542,"type":37},"2024-12-05",{"date":544,"type":37},"2021-05-17",{"date":540,"type":20},{"name":547,"class":90},"University of Sao Paulo",{"id":549,"slug":550,"hasResults":11,"nctId":551,"briefTitle":552,"officialTitle":553,"acronym":4,"eligibilityCriteria":554,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":555,"targetDuration":4,"studyType":56,"phases":557,"briefSummary":558,"conditions":559,"keywords":561,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":566,"lastUpdatePostDateStruct":567,"startDateStruct":569,"completionDateStruct":571,"leadSponsor":573,"locationsCount":43},"100547895","evaluation-of-cognitive-behavioral-therapy-for-long-term-pain-in-rheumatic-disease-including-validation-of-ae-fs-100547895","NCT06413914","Evaluation of Cognitive Behavioral Therapy for Long-term Pain in Rheumatic Disease, Including Validation of AE-FS","Evaluation of Cognitive Behavioral Therapy for Long-term Pain in Rheumatic Disease, Including Validation the Questionnaire of AE-FS","Inclusion Criteria:\n\n* A rheumatic disorder and a long term pain condition\n* Written consent\n\nExclusion Criteria:\n\n* Participation in another therapy during the study periode",{"count":556,"type":20},200,[58],"Catastrophic thinking is a risk factor for a poor prognosis for pain in general and rheumatic disease in particular, which for many contributes to a behavioral pattern characterized by avoidance. Other people with long-term pain, on the other hand, have a pattern where they suppress thoughts and feelings of fear associated with pain, and push themselves to carry out activities. An inappropriate form of endurance can help maintain and intensify pain. The AE-FS is a short version of the Avoidance-Endurance Questionnaire with different subscales for maintaining activity despite pain. AE-FS can be of great clinical utility. The study of patients with rheumatic disease and long-term pain will validate a Norwegian version of the AE-FS as well as examine how the AE-FS seen in connection with other relevant questionnaires, including the Pain Catastrophizing Scale , reflects mechanisms for change in cognitive behavioral therapy for long-term pain. The effect of the intervention is evaluated with questionnaires at baseline\u002Fstart of treatment, end of treatment, two months after end of treatment and after six months.",[24,560],"Pain, Chronic",[562,563,564,565],"\"Cognitive behavioral therapy\"","Long-term pain","Avoidance-Endurance Questionnaire","Rheumatic disease","2024-10-09",{"date":568,"type":37},"2024-10-15",{"date":570,"type":37},"2024-01-16",{"date":572,"type":20},"2030-12-31",{"name":574,"class":90},"Diakonhjemmet Hospital",{"id":576,"slug":577,"hasResults":11,"nctId":578,"briefTitle":579,"officialTitle":579,"acronym":580,"eligibilityCriteria":581,"healthyVolunteers":52,"sex":15,"minAge":582,"maxAge":362,"enrollmentInfo":583,"targetDuration":584,"studyType":21,"phases":4,"briefSummary":585,"conditions":586,"keywords":588,"overallStatus":80,"whyStopped":4,"lastUpdateSubmitDate":592,"lastUpdatePostDateStruct":593,"startDateStruct":595,"completionDateStruct":597,"leadSponsor":598,"locationsCount":43},"100555721","use-of-thermography-for-the-prevention-and-diagnosis-of-rheumatic-foot-100555721","NCT06515769","Use of Thermography for the Prevention and Diagnosis of Rheumatic Foot","TG-AR","Inclusion Criteria:\n\n* Patients with rheumatoid arthritis of more than 5 years\\' duration\n* Healthy patients without diagnosed systemic disease\n* Patients between 40 and 80 years of age\n\nExclusion Criteria:\n\n* Patients who are pregnant or may become pregnant\n* Patients with degenerative diseases or significant cognitive impairment\n* Patients with rheumatic diseases without a diagnosis of rheumatoid arthritis","40 Years",{"count":556,"type":20},"6 Months","The aim of this observational study is to establish normal thermographic parameters in patients with rheumatoid arthritis, in order to prevent and diagnose rheumatic foot using thermography. The main question to be answered is: What are the normal thermographic parameters in rheumatic foot?\n\nIf there is a comparison group: the researchers will compare the thermography of the foot in healthy subjects and in subjects with rheumatoid arthritis to see if there are any alterations in the thermographic image.\n\nPatients who wish to participate in the study will undergo a thermographic study of the foot, which does not entail any risk to their health.",[199,587,24],"Rheumatoid Arthritis RA",[589,199,590,591],"Rheumatic foot","Rheumatic diseases","Thermoghrapy","2024-07-17",{"date":594,"type":37},"2024-07-23",{"date":596,"type":20},"2024-09-01",{"date":284,"type":20},{"name":599,"class":90},"University of Seville",{"id":601,"slug":602,"hasResults":11,"nctId":603,"briefTitle":604,"officialTitle":605,"acronym":4,"eligibilityCriteria":606,"healthyVolunteers":11,"sex":15,"minAge":607,"maxAge":16,"enrollmentInfo":608,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":609,"conditions":610,"keywords":613,"overallStatus":80,"whyStopped":4,"lastUpdateSubmitDate":619,"lastUpdatePostDateStruct":620,"startDateStruct":622,"completionDateStruct":624,"leadSponsor":626,"locationsCount":43},"100551490","validity-and-reliability-of-the-inflammatory-arthritis-facilitators-and-barriers-to-physical-activity-questionnaire-100551490","NCT06460766","Validity and Reliability of the Inflammatory Arthritis Facilitators and Barriers to Physical Activity Questionnaire","Validity and Reliability of the Inflammatory Arthritis Facilitators and Barriers to Physical Activity (IFAB) Questionnaire for Individuals With Pediatric Rheumatic Disease","Inclusion Criteria:\n\n* Volunteer\n* 12-18 ages\n* Diagnosed with juvenile idiopathic arthritis, juvenile dermatomyositis and juvenile fibromyalgia syndrome by a pediatric rheumatologist\n* Residing in Turkey\n\nExclusion Criteria:\n\n* Having a vision or hearing problem\n* Difficulty adhering to the treatment program","12 Years",{"count":222,"type":20},"No tool has been found to evaluate behaviors that may hinder or facilitate physical activity in individuals with pediatric rheumatic diseases. In this sense, the importance of examining physical activity barriers and facilitators in children with rheumatic diseases is clear. We believe that our study will guide the increase in physical activity, which is very important for reducing disease risks in individuals with pediatric rheumatic diseases. The aim of our study is to examine the validity and reliability of the Inflammatory Arthritis Facilitators and Barriers to Physical Activity (IFAB) Questionnaire in individuals with pediatric rheumatic diseases (juvenile idiopathic arthritis, juvenile fibromyalgia syndrome, juvenile dermatomyositis).",[24,611,612],"Pediatric ALL","Children, Only",[614,615,616,617,618],"pediatric rheumatic disease","physical activity","juvenile idiopathic arthritis","juvenile dermatomyositis","juvenile fibromyalgia syndrome","2024-06-11",{"date":621,"type":37},"2024-06-14",{"date":623,"type":20},"2024-07",{"date":625,"type":20},"2024-10",{"name":627,"class":90},"Istanbul University - Cerrahpasa",{"id":629,"slug":630,"hasResults":11,"nctId":631,"briefTitle":632,"officialTitle":633,"acronym":4,"eligibilityCriteria":634,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":635,"enrollmentInfo":636,"targetDuration":4,"studyType":56,"phases":638,"briefSummary":639,"conditions":640,"keywords":643,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":647,"lastUpdatePostDateStruct":648,"startDateStruct":650,"completionDateStruct":652,"leadSponsor":654,"locationsCount":43},"100545720","technological-based-rehabilitation-on-individuals-with-rheumatic-disease-100545720","NCT06385574","Technological Based Rehabilitation on Individuals With Rheumatic Disease","The Effects of Technological Based Rehabilitation on Individuals With Rheumatic Disease With Hand Involvement","Inclusion Criteria:\n\n* Having been diagnosed with a rheumatic disease that meets the latest criteria by a rheumatologist\n* Involvement in hand joints (pain, swelling, tenderness)\n* Being 18 years or older\n* Being on stable drug treatment for the last 6 months\n* Having sufficient cooperation to participate in the study\n* Volunteering to participate in the study\n\nExclusion Criteria:\n\n* Not volunteering to participate in the study\n* Having difficulty in cooperating at work\n* Having an additional orthopedic and\u002For neurological disease that will affect hand functions","64 Years",{"count":637,"type":20},45,[58],"Affects such as pain, swelling, tenderness, deformities, limitations, strength and function losses, skill and coordination deficiencies in the hand joints, which are frequently seen in rheumatism patients with hand involvement, are included in body structure and function disorders within the framework of International Classification of Function System. Leap Motion Controller is used in hand rehabilitation because it is small in size, low-cost, portable, non-contact, easy to use and provides visual and auditory feedback. The aim of our study is to examine the effect of technology-based rehabilitation on joint range of motion, grip strength, functionality and disease activity in adult individuals with rheumatic disease with hand involvement; and also to compare these effects with the effects of the hand rehabilitation program implemented under the guidance of a physiotherapist and the control group that continues its routine life.",[24,641,642],"Hand Rheumatism","Virtual Reality Therapy",[227,644,645,646],"hand exercises","leap motion","functionality","2024-06-07",{"date":649,"type":37},"2024-06-10",{"date":651,"type":37},"2024-03-15",{"date":653,"type":20},"2024-06-20",{"name":655,"class":90},"Akdeniz University",{"id":657,"slug":658,"hasResults":11,"nctId":659,"briefTitle":660,"officialTitle":661,"acronym":662,"eligibilityCriteria":663,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":362,"enrollmentInfo":664,"targetDuration":4,"studyType":56,"phases":666,"briefSummary":667,"conditions":668,"keywords":4,"overallStatus":80,"whyStopped":4,"lastUpdateSubmitDate":674,"lastUpdatePostDateStruct":675,"startDateStruct":677,"completionDateStruct":678,"leadSponsor":679,"locationsCount":4},"100537090","towards-telemonitoring-in-immune-mediated-inflammatory-diseases-implementation-of-a-mixed-attention-model-imidoc-100537090","NCT06273306","Towards Telemonitoring in Immune-Mediated Inflammatory Diseases: Implementation of a Mixed Attention Model (IMIDOC)","Towards Telemonitoring in Immune-Mediated Inflammatory Diseases: Implementation of a Mixed Attention Model","IMIDOC","Inclusion Criteria:\n\n* Clinical diagnosis with Rheumatoid Arthritis or Spondylarthritis\n* Treatment with biologic or targeted disease modifying antirheumatic drugs.\n* Ability to use smartphone.\n\nExclusion Criteria:\n\n* only patients with conditions that hinder or prevent the use of a mobile application (blindness, mental retardation, dementia, digitalfilliteracy).",{"count":665,"type":20},360,[58],"The main objective is to evaluate the implementation of a hybrid care model called the mixed attention model (MAM) in clinical practice and to evaluate whether its implementation improves clinical outcomes compared to conventional follow-up.\n\nThis is a multicenter prospective observational study involving 360 patients with rheumatoid arthritis (RA) and Spondylarthritis (SpA) from five Spanish Hospitals. Patients will be followed-up by the MAM protocol, which is a care model that incorporates the use of digital tool consisting of a mobile application (App) that patients can use at home and that professionals can review asynchronously to detect incidents and to follow their patients; clinical evolution between face-to-face visits. Another group of patients, whose follow-up will be conducted in accordance with a traditional face-to-face care model, will be assessed as the control group. Sociodemographic characteristics, treatments, laboratory parameters, assessment of tender and swollen joints, visual analogue scale for pain and electronic patient reported outcome reports (ePROs) will be collected for all subjects. In the MAM group, these items will be self-assessed both by the mobile App and during face-to-face visits with rheumatologist, who will do the same for patients included in the traditional care model. Patients will be able to report any incidence related to their disease or treatment through the mobile App.",[669,670,671,24,672,673],"Telemedicine","Telehealth","eHealth","Arthritis, Rheumatoid","Spondylarthritis","2024-02-15",{"date":676,"type":37},"2024-02-22",{"date":651,"type":20},{"date":238,"type":20},{"name":680,"class":90},"Instituto de Investigación Hospital Universitario La Paz",{"id":682,"slug":683,"hasResults":11,"nctId":684,"briefTitle":685,"officialTitle":686,"acronym":687,"eligibilityCriteria":688,"healthyVolunteers":52,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":689,"targetDuration":155,"studyType":21,"phases":4,"briefSummary":691,"conditions":692,"keywords":699,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":700,"lastUpdatePostDateStruct":701,"startDateStruct":703,"completionDateStruct":705,"leadSponsor":707,"locationsCount":43},"100439826","ild-sards-registry-and-biorepository-100439826","NCT05007340","ILD-SARDs Registry and Biorepository","Interstitial Lung Disease in Systemic Autoimmune Rheumatic Diseases (ILD-SARDs) Registry and Biorepository","ILD-SARDs","Inclusion Criteria:\n\n1. Must be aged 18 years or older\n2. Diagnosis of ILD as confirmed by a chest CT\n3. Either a defined SARD, an undifferentiated connective tissue disease or features of autoimmunity without meeting clinical criteria for SARD\n4. Patient must be willing to give their informed consent and must be able to understand and follow the required study procedures.\n\nExclusion Criteria:\n\nN\u002FA",{"count":690,"type":20},252,"A complex interaction between demographic, environmental and genetic mechanisms impact the onset, severity and outcome of ILD-SARDs through dysregulation of the immune system and lung pro-biotic pathways. Comorbidity and genetic risk indicate that there are overlapping pathogenic mechanisms among SARDs, some of which underlie ILD in different SARDs.\n\nThe purpose of this biobank is to study the clinical, pathological, laboratory, and imaging characteristics of SARDs patients with lung involvement. This will help identify as unique features underlying lung involvement in SARDs. In addition, this may lead to the discovery of novel mechanisms of disease and potentially novel targets of treatment for SARDs patients with lung disease.",[693,694,24,695,201,696,191,697,698],"Interstitial Lung Disease","Systemic Autoimmune Disease","Rheumatic Arthritis","Autoimmune Myositis","Usual Interstitial Pneumonia","Nonspecific Interstitial Pneumonia",[693,694,24,695,201,696,191,697,698],"2021-09-01",{"date":702,"type":37},"2021-09-09",{"date":704,"type":37},"2021-08-24",{"date":706,"type":20},"2026-08",{"name":119,"class":90}]